Form 4: MindMed Director Andreas Krebs Granted 75,187 Stock Options

Mind Medicine (MindMed) Inc. Director Andreas Krebs was granted 75,187 stock options with an exercise price of $7.3, vesting monthly over a year or earlier upon the company's annual meeting.

Summary

• Andreas Krebs, a Director of Mind Medicine (MindMed) Inc. (MNMD), was granted stock options.
• The transaction date for the grant was June 12, 2025.
• A total of 75,187 stock options were acquired.
• The exercise price for these options is $7.3 per share.
• The stock options have an expiration date of June 11, 2035.
• The options vest and become exercisable as to 1/12th of the underlying shares on each monthly anniversary of the grant date.
• Alternatively, if the Company's annual meeting immediately following the grant date takes place prior to the first anniversary, the options will vest immediately prior to that annual meeting.
• Vesting is subject to Mr. Krebs' continued service through the applicable vesting date.
• Following this transaction, Andreas Krebs beneficially owns 75,187 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The document reports a routine equity compensation grant to a director, which is a standard practice for aligning interests and is generally viewed as a neutral to slightly positive event, indicating continued commitment.

Positives

• The grant of stock options to a director aligns their long-term interests with those of the company's shareholders, incentivizing performance and value creation.

Future Outlook

The stock options are subject to a vesting schedule over the next year, indicating a long-term incentive for the director and aligning their future interests with the company's performance and potential future share price appreciation.

Industry Context

This Form 4 filing is a routine disclosure of equity compensation for a director, a common practice in publicly traded companies to align management and board interests with shareholder value. Such grants are standard components of executive and board compensation packages.

Comparison to Industry Standards

• Granting stock options to directors is a common industry practice for executive and board compensation, aiming to incentivize long-term performance and align interests with shareholders.
• The specific terms, including the exercise price and vesting schedule, are typical for such equity grants, though the overall value and number of options granted would depend on the company's market capitalization, compensation philosophy, and the director's role and responsibilities.

Stakeholder Impact

• Shareholders: The grant of stock options aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through increased focus on value creation.

Next Steps

• The granted stock options will vest monthly over the next year, or potentially sooner upon the company's annual meeting, subject to the director's continued service.
• Upon vesting, the director will have the right to exercise these options to acquire common shares of Mind Medicine (MindMed) Inc. at the specified exercise price.

Key Dates

Keywords

Mind Medicine, MNMD, Stock Option, Insider Transaction, Form 4, Andreas Krebs, Director, Equity Compensation, Vesting